ArticleCancer immunology, immunotherapy : CII2015

A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.

Eleftheria A Anastasopoulou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.